Investigating how lowering mutant Huntingtin affects aging in Huntington's disease models
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
This study is looking at how lowering a harmful protein linked to Huntington's disease might help slow down the disease as people get older, using specially modified mice to find the best ways to do this for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11023108 on NIH RePORTER |
What this research studies
This research focuses on understanding how reducing the levels of mutant Huntingtin protein can influence the progression of Huntington's disease, particularly in aging models. By using genetically modified mice, the study examines the timing and effectiveness of different strategies to lower this protein, which is known to contribute to the disease's symptoms. The researchers aim to identify the best approaches for treatment that could potentially improve outcomes for patients with Huntington's disease as they age.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Huntington's disease, especially those who are experiencing symptoms related to aging.
Not a fit: Patients with early-stage Huntington's disease who are not yet experiencing significant symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Huntington's disease, particularly for older patients.
How similar studies have performed: Other research has shown promising results with similar approaches to lowering mutant Huntingtin, indicating potential for success in this study.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Zeitlin, Scott — University of Virginia
- Study coordinator: Zeitlin, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.